Compare TRVI & IIPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRVI | IIPR |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United States | United States |
| Employees | N/A | 23 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 2019 | N/A |
| Metric | TRVI | IIPR |
|---|---|---|
| Price | $13.47 | $54.38 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 3 |
| Target Price | $21.55 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 1.6M | 351.9K |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 14.28% |
| EPS Growth | ★ 31.91 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $2.69 |
| Revenue Next Year | N/A | $3.80 |
| P/E Ratio | ★ N/A | $10.92 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.38 | $44.58 |
| 52 Week High | $16.12 | $61.40 |
| Indicator | TRVI | IIPR |
|---|---|---|
| Relative Strength Index (RSI) | 44.66 | 50.25 |
| Support Level | $13.11 | $54.23 |
| Resistance Level | $13.97 | $58.02 |
| Average True Range (ATR) | 0.81 | 2.05 |
| MACD | -0.13 | -0.32 |
| Stochastic Oscillator | 15.30 | 21.10 |
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
Innovative Industrial Properties Inc is a real estate investment trust focused on the acquisition, ownership and management of specialized industrial and commercial properties in the United States. Its properties are prominently leased to state-licensed operators for their regulated cannabis facilities. The company conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by its Operating Partnership, directly or through subsidiaries. Its segments are: Cannabis Portfolio and Life Science Portfolio, with the majority of revenue coming from the Cannabis Portfolio segment, which involves acquiring, developing, and leasing real estate to regulated cannabis operators on long-term triple-net leases.